Joon Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Pediatric behavioral health game rewarding children with ADHD and autism for completing real-world therapeutic tasks; 20K+ paying subscribers YC-backed competing with Brightline for child mental health.
About
Joon Health is a New York-based pediatric digital health company using gamification to treat behavioral health disorders in children — including ADHD, autism spectrum disorder, anxiety, and depression — by rewarding children in a mobile game for completing real-world therapeutic activities (behavior management tasks, coping skills exercises, routines) that parents and clinicians prescribe through the platform. Founded in 2021 and backed by Y Combinator with $6+ million raised, Joon Health launched in January 2022 and grew to 20,000+ active paying subscribers.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.